サンプル依頼リスト カート
  • English
  • Korean
表紙：甲状腺腫治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1352188

甲状腺腫治療の世界市場-2023年～2030年

Global Goitre Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
甲状腺腫治療の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の甲状腺腫治療市場は、有病率の増加、臨床試験の増加、研究活動、その他の活動など、そのダイナミクスに影響を与えるさまざまな要因によって、長年にわたって大きな成長と変貌を遂げてきました。より良い治療法の開発に対する政府の投資は、世界市場を引き続き牽引し、後押しするものと思われます。全体として、世界の甲状腺腫治療市場は今後数年間で急速な成長が見込まれます。

甲状腺腫は主に甲状腺の不規則な成長を特徴とします。甲状腺腫の治療には、甲状腺ホルモン補充療法、抗甲状腺薬、ベータ遮断薬、鎮痛剤、放射性ヨード治療、手術（甲状腺摘出術）などが含まれます。治療分野では放射性ヨード治療が最大の市場シェアを占めると予想され、第一選択治療と考えられています。同様に、北米が市場を独占しており、同地域の先進医療インフラと有利な償還政策により最大の市場シェアを獲得しています。

さらに、甲状腺腫の有病率の増加、規制当局の承認、認知度の向上と早期発見、新規治療薬の臨床試験の増加、個別化医薬品の需要の増加、治療オプションの進歩が、予測期間にわたって世界の甲状腺腫治療市場を牽引すると予想される主な要因です。しかし、代替治療オプションの利用可能性と治療に伴う副作用は、市場成長を妨げると予想される要因です。

ダイナミクス

新規治療薬の臨床試験の増加が市場の成長を促進すると予想される

新規治療薬に対する需要の高まりが、予測期間中の世界市場を牽引すると予想されます。患者の予後を改善するための新規治療薬の開発に向けて、臨床試験は現在も進行中です。現在利用可能な治療法や治療薬は、治療が甲状腺腫大や甲状腺ホルモンレベルに基づいているため、すべての患者に有効とは言えず、また、より良い、より強化された治療結果を達成できる新しい治療法や治療薬の必要性もあります。

さらに、革新的な治療法を開発するためには、新規治療法を開発する際の安全性の懸念や有効性を検討するための臨床試験が非常に重要です。甲状腺腫の有病率は増加の一途をたどっており、例えばクリーブランド・クリニック（Cleveland Clinic）という組織によると、甲状腺腫は推定22億人に影響を与えています。このような有病率の増加は、より多くの研究を行うのに役立っています。また、多くの比較研究は、より良い結果や異なる作用機序を持つ新しい治療法や療法を進化させるのに役立っています。

例えば、2023年7月2日、国立台湾大学病院は、甲状腺または副甲状腺手術中の癒着防止バリアの効果を前向きに比較する臨床試験を開始したと発表しました。この研究は、甲状腺腫、甲状腺がん、甲状腺摘出状態の治療のために、酸化再生セルロース薬剤、ヒアルロン酸薬剤などの薬剤の治療や介入を開発するために行われています。

意識の高まりと早期発見が市場の成長を牽引すると予想される

認知度の向上と早期発見が、予測期間中の市場の牽引役となることが期待されます。甲状腺腫の徴候や症状に関する認知度の向上は、甲状腺腫の早期発見と診断に役立ち、さらに、手術のようなより積極的な介入の必要性を減らす可能性のある、より良い治療を管理し求めるのに役立ちます。

さらに、早期発見は、特にヨウ素欠乏が甲状腺腫の一般的な原因である地域では、個人が予防措置を講じるのにも役立ちます。こうした対策には、ヨウ素摂取量を増やすための食生活の改善や、ヨウ素添加塩の使用が含まれます。意識が高まるにつれ、甲状腺機能を正確に評価し甲状腺腫を発見できる診断ツールや検査に対する需要が高まる可能性があります。

意識の高まりは、患者教育や支援サービスの必要性の高まりにもつながります。甲状腺腫や甲状腺疾患の患者は、その状態の管理、食事の推奨、服薬アドヒアランスに関する情報を必要とする可能性があり、医療提供者や支援組織に機会を創出します。

例えば、国家栄養評議会によると、2006年12月11日にグロリア・マカパガル・アロヨ前大統領が署名した布告第1188号により、1月の第4週は甲状腺腫啓発週間（GAW）と宣言されています。これは、甲状腺腫とヨウ素欠乏症についての認識をさらに広め、大衆を教育するための情報発信も含むこの年中行事を成功させるためのガイドラインとロジスティクスを策定するためです。

代替治療オプションの利用が市場成長の妨げになる見通し

代替治療オプションの利用可能性は、予測期間における市場成長の妨げになると予想されます。個人によっては、ハーブ療法や栄養補助食品など、甲状腺腫を管理するために補完代替医療のアプローチを模索することを選択するかもしれません。これらのアプローチは確かな科学的根拠によって裏付けられていないかもしれませんが、非従来型の治療法を求めている人々に代替手段を提供することができます。

さらに、ハーブサプリメントや自然療法は甲状腺の問題を抱えている人がよく考慮するものです。食生活の調整やストレス管理法などのライフスタイルの変化が代替医療の実践者から勧められることもあります。これらのアプローチは、従来の医学的治療の代替と見なされることがあり、甲状腺腫治療市場の妨げとなっています。

治療に伴う副作用も市場成長の妨げになる

甲状腺腫治療に伴う副作用は、予測期間における市場成長の妨げになると予想されます。患者が薬や治療による不快な副作用を経験すると、処方された治療を守る可能性が低くなります。コンプライアンス不良は最適な治療結果を得られず、病状を悪化させる可能性があるため、市場の成長を制限する可能性があります。

さらに、副作用を恐れるあまり、甲状腺腫の治療を受けようとしない人もいます。その結果、診断と治療が遅れ、病状がさらに進行する可能性があります。既存の治療法に伴う重大な副作用の存在は、より安全で効果的な治療法を発見するための研究開発努力を促し、既存の治療法と競合する新しい治療法の導入につながる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新規治療薬の臨床試験の増加
      • 意識の高まりと早期発見
    • 抑制要因
      • 代替治療オプションの利用可能性
      • 治療に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ紛争分析
  • DMIの見解

第6章 COVID-19分析

第7章 甲状腺腫の種類別

  • 腫大に基づく
    • 単純性（びまん性）甲状腺腫
    • 結節性甲状腺腫
    • 多結節性甲状腺腫
  • 甲状腺ホルモン値に基づく
    • 中毒性甲状腺腫
    • 無毒性甲状腺腫

第8章 治療法別

  • 甲状腺ホルモン補充療法
  • 抗甲状腺薬
  • ベータ遮断薬
  • 鎮痛剤
  • 放射性ヨード治療
  • 手術（甲状腺摘出術）
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 耳鼻咽喉科クリニック
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Abbvie Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Merck KGaA
  • Pfizer Inc.
  • Viatris Inc.
  • Exelixis Inc.
  • Abbott Laboratories
  • Mylan Laboratories Inc.
  • Lannett Company, Inc.
  • BTG International Inc.
  • ANBEX INC.

第13章 付録

目次
Product Code: PH6940

Overview

The global goitre treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics such as increasing prevalence, rising clinical trials, research activities, and others. Government investments in the development of better treatment will continue to drive and boost the global market. Overall, the global goitre treatment market is expected to experience rapid growth in the coming years.

The goitre is mainly characterized by the irregular growth of the thyroid gland. The treatment of goiter includes thyroid hormone replacement therapy, anti-thyroid drugs, beta-blockers, pain relievers, radioactive iodine treatment, surgery (thyroidectomy), and others. The radioactive iodine treatment is expected to hold the largest market share from the treatment segment and is considered a first-line treatment. Similarly, North America dominates the market, capturing the largest market share owing to the region's advanced healthcare infrastructure, and favorable reimbursement policies.

Moreover, owing to the increasing prevalence of goitre, regulatory approvals, growing awareness and early detection, rising clinical trials for novel therapeutics, increasing demand for personalized medicines, and advancements in treatment options are the major factors expected to drive the global goitre treatment market over the forecast period. However, the availability of alternative treatment options and adverse effects associated with the treatment are the factors expected to hamper the market growth.

Dynamics

Rising Clinical Trials for Novel Therapeutics is Expected to Drive the Growth of the Market

There is an increasing demand for novel therapeutics, which is expected to drive the global market over the forecast period. Clinical trials are still going on for the development of novel therapeutics for better patient outcomes. The currently available treatments and therapeutics are not effective for all patients due to the treatment is based on thyroid enlargement and thyroid hormone levels, and there is also a need for new therapies and therapeutics that can achieve better and enhanced treatment results.

Moreover, for the development of innovative treatment options, clinical trials are very important to consider the safety concerns and efficacy of developing novel therapeutics. There is a continuously increasing prevalence of the goitre, for instance, according to the Cleveland Clinic organization, goitre affects an estimated 2.2 billion people. This increasing prevalence helps to perform more studies. Many comparison studies also helps to evolve new therapies and therapeutics with better results and with different mechanisms of action.

For instance, on July 2, 2023, the National Taiwan University Hospital announced that they started clinical trials for prospective comparison of the effect of antiadhesive barriers during thyroid or parathyroid surgery. The study is performing to develop the treatment or intervention of drugs such as oxidized regenerated cellulose drugs, and hyaluronic acid drugs for the treatment of goiter, thyroid cancer, and thyroidectomy conditions.

Growing Awareness and Early Detection is Expected to Drive the Growth of the Market

The growing awareness and early detection are expected to drive the market over the forecast period. Increased awareness about the signs and symptoms of goitre can helps to earlier detection and diagnosis of the condition, which further helps to manage and seeks the better treatment potentially reducing the need for more aggressive interventions like surgery.

Moreover, early detection can also helps individuals to take preventive measures, especially in regions where iodine deficiency is a common cause of goitre. These measures may include dietary changes to increase iodine intake or the use of iodized salt. As awareness grows, there may be a higher demand for diagnostic tools and tests that can accurately assess thyroid function and detect goitre.

Growing awareness can also lead to a greater need for patient education and support services. Patients with goitre and thyroid disorders may require information on managing their condition, dietary recommendations, and medication adherence, creating opportunities for healthcare providers and support organizations.

For instance, according to the National Nutrition Council, the fourth week of January is declared as Goiter Awareness Week (GAW) through Proclamation No. 1188 signed by former President Gloria Macapagal Arroyo on the 11th day of December 2006. This is to formulate guidelines and logistics to ensure the success of the yearly event which also includes information dissemination to further spread awareness and educate the masses about goiter and iodine deficiency disorders.

Availability of Alternative Treatment Options Expected to Hamper the Market's Growth

The availability of alternative treatment options is expected to hamper the market growth over the forecast period. Some individuals may choose to explore complementary and alternative medicine approaches to manage the goitre, such as herbal remedies, or dietary supplements. While these approaches may not be supported by robust scientific evidence, they can provide alternatives for those who are seeking non-conventional treatments.

Moreover, herbal supplements and natural remedies are often considered by individuals with thyroid issues. Lifestyle changes, including dietary adjustments and stress management techniques, may be recommended by alternative medicine practitioners. These approaches can be seen as an alternative to conventional medical treatments, which hampers the goitre treatment market.

Adverse Effects Associated with the Treatment Will also Hamper the Market Growth

The adverse effects associated with the goitre treatment are expected to hamper the market growth over the forecast period. If patients experience unpleasant side effects from medications or treatments, they may be less likely to adhere to their prescribed treatments. Poor compliance can lead to suboptimal treatment outcomes and potentially worsen the condition, which can limit the market's growth.

Furthermore, the fear of adverse effects can discourage some individuals from seeking medical treatment for goitre. This can result in delayed diagnosis and treatment, which may lead to more advanced stages of the condition. The presence of significant adverse effects associated with existing treatments can drive research and development efforts to discover safer and more effective therapies, potentially leading to the introduction of new treatments that compete with existing ones.

Segment Analysis

The global goitre treatment market is segmented based on goitre type, treatment, end-user and region.

The Radioactive Iodine Treatment Segment Accounted for Approximately 37.8% of the Goitre Treatment Market Share

Radioactive iodine treatment is expected to hold the largest market share over the forecast period. Treatment for goiter especially depends on the factors such as how large the thyroid has grown, symptoms, and what caused it. The radioactive iodine treatment is used in cases of an overactive thyroid gland and involves taking radioactive iodine orally. The iodine directly goes to the thyroid gland and helps to kill the thyroid cells, which results in shrinking the gland. After radioactive iodine treatment, it's better to take thyroid hormone replacement therapy for the rest of the life to avoid further complications.

Moreover, the radioactive iodine treatment is an older and best method for enhanced and better treatment. Following radioactive iodine treatment, patients with goitre can be monitored over the long term using radioactive iodine scans and blood tests. This provides a valuable tool for ongoing goitre management. Radioactive iodine is taken up primarily by thyroid tissue, making it a highly targeted therapy. This means it has minimal impact on other tissues and organs in the body, reducing the risk of side effects compared to more systemic treatments.

For instance, according to the National Institute of Health (NIH), Dr. Saul Hertz, founding director of Massachusetts General Hospital Thyroid Clinic, affiliated with Harvard University created a framework for radioactive iodine theranostics with preclinical experiments and clinical cases from 1937 to 1942. The first thyroid cancer treatment with radioactive iodine was applied in 1942 by Samuel Seidlin. This radioactive iodine treatment is applied for the treatment of thyroid cancer, goiter, and some iodine deficiency disorders.

Geographical Penetration

North America Accounted for Approximately 39.1% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Favorable Reimbursement Policies

North America is expected to hold the largest market share over the forecast period owing to the advanced healthcare infrastructure and favorable reimbursement policies. North America, especially the United States and Canada is very well known for its advanced healthcare infrastructure including hospitals, specialty clinics, research centers, ENT clinics, and others. This advanced healthcare infrastructure helps to treat patients in a better way.

According to the Cleveland Clinic Organization, goiter affects about 5% of people in the United States. This increasing prevalence can be controlled by advanced healthcare infrastructure by early detection and advanced treatment.

Furthermore, North America is also known for its favorable reimbursement policies for offering patients which helps for effective treatment and early prevention. The improved insurance coverage offers the better treatment for many patients at affordable costs without the burden to the goitre patients, leading to market dominance in the region.

Competitive Landscape

The major global players in the goitre treatment market include Abbvie Inc., Merck KGaA, Pfizer Inc., Viatris Inc., Exelixis Inc., Abbott Laboratories, Mylan Laboratories Inc., Lannett Company, Inc., BTG International Inc., and ANBEX INC. among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global goitre treatment market. During the pandemic, many clinical trials, and research activities to develop new treatment options, have been temporarily postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular thyroid and goiter check-ups, appointments, and consultations worldwide due to many hospitals being focused on COVID-19 cases, this reduced thyroid-related treatments including goitre treatment impacted the global market.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials of goiter-related therapeutics such as anti-thyroid drugs, beta-blockers, and others. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global goitre treatment market. Many clinical trials and research activities are temporarily disrupted. The conflict has less impact mainly due to the low prevalence and absence of key market players in this region. The impact of the import and export of raw materials is expected to have little influence over the global market growth over the forecast period.

By Goitre Type

  • Based on Enlargement
    • Simple (Diffuse) Goitre
    • Nodular Goitre
    • Multinodular Goitre
  • Based on Thyroid Hormone Levels
    • Toxic Goitre
    • Nontoxic Goitre

By Treatment

  • Thyroid Hormone Replacement Therapy
  • Anti-Thyroid Drugs
  • Beta Blockers
  • Pain Relievers
  • Radioactive Iodine Treatment
  • Surgery (Thyroidectomy)
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • ENT Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On January 18, 2023, drug major Cipla said that it has launched a diagnostic device for various conditions including diabetes, infectious diseases, and thyroid function. The product, Cippoint, a point-of-care testing device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions.
  • On November 19, 2021, Swiss medtech company Bloom Diagnostics launched its Bloom Thyroid Test to help detect hypothyroidism. Bloom Diagnostics is an innovative MedTech company that has developed a smart self-testing system for a wide range of medical conditions. The single-use kit can be used to test adults for thyroid-stimulating hormone (TSH) as a means of detecting thyroid dysfunction in adults. The Bloom Thyroid test received the approval certificate from the Notified Body, which will allow lay users to perform the test at home.

DataM Intelligence Opinion:

According to the DataM Intelligence, the goitre treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years owing to its increasing prevalence mainly due to iodine deficiency and many companies are focusing to develop novel therapeutic innovations for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global goitre treatment market in the upcoming years.

Why Purchase the Report?

  • To visualize the global goitre treatment market segmentation based on goitre type, treatment, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of goitre treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global goitre treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Goitre Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Clinical Trials for Novel Therapeutics
      • 4.1.1.2. Rising Awareness and Early Detection
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Alternative Treatment Options
      • 4.1.2.2. Adverse Effects Associated with the Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine Conflict Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Goitre Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Goitre Type
    • 7.1.2. Market Attractiveness Index, By Goitre Type
  • 7.2. Based on Enlargement *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Simple (Diffuse) Goitre
    • 7.2.4. Nodular Goitre
    • 7.2.5. Multinodular Goitre
  • 7.3. Based on Thyroid Hormone Levels
    • 7.3.1. Toxic Goitre
    • 7.3.2. Nontoxic Goitre

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Thyroid Hormone Replacement Therapy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Anti-Thyroid Drugs
  • 8.4. Beta Blockers
  • 8.5. Pain Relievers
  • 8.6. Radioactive Iodine Treatment
  • 8.7. Surgery (Thyroidectomy)
  • 8.8. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. ENT Clinics
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Goitre Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Goitre Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Goitre Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Goitre Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Goitre Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbvie Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Merck KGaA
  • 12.3. Pfizer Inc.
  • 12.4. Viatris Inc.
  • 12.5. Exelixis Inc.
  • 12.6. Abbott Laboratories
  • 12.7. Mylan Laboratories Inc.
  • 12.8. Lannett Company, Inc.
  • 12.9. BTG International Inc.
  • 12.10. ANBEX INC.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us